Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2016 2
2017 5
2018 8
2019 8
2020 5
2021 8
2022 10
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
Heger JM, d'Hargues Y, Kleinert F, Mattlener J, Weiss J, Franzen F, Becker C, Becker K, Gödel P, Schmiel M, Meinel J, Flümann R, Simon F, Reinhardt HC, Borchmann P, Borchmann S, Balke-Want H, Knittel G, von Tresckow B. Heger JM, et al. Among authors: borchmann s. Eur J Haematol. 2024 Jun;112(6):957-963. doi: 10.1111/ejh.14191. Epub 2024 Feb 18. Eur J Haematol. 2024. PMID: 38369814
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM, Mattlener J, Schneider J, Gödel P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Rueß D, Ruge MI, Montesinos-Rongen M, Deckert M, Blau T, Kutsch N, Balke-Want H, Weiss J, Becker K, Reinhardt HC, Hallek M, Borchmann P, von Tresckow B, Borchmann S. Heger JM, et al. Among authors: borchmann s. Blood. 2024 Feb 8;143(6):522-534. doi: 10.1182/blood.2023022020. Blood. 2024. PMID: 37946299
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT. Borchmann S, et al. J Immunother Cancer. 2022 Oct;10(10):e004781. doi: 10.1136/jitc-2022-004781. J Immunother Cancer. 2022. PMID: 36223955 Free PMC article.
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
Gillessen S, Pluetschow A, Vucinic V, Ostermann H, Kobe C, Bröckelmann PJ, Böll B, Eichenauer DA, Heger JM, Borchmann S, Fuchs M, Borchmann P, Engert A, von Tresckow B. Gillessen S, et al. Among authors: borchmann s. Eur J Haematol. 2022 Dec;109(6):728-735. doi: 10.1111/ejh.13859. Epub 2022 Oct 3. Eur J Haematol. 2022. PMID: 36056778 Clinical Trial.
Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment.
Drees EEE, Jauw YWS, van Dijk E, Borchmann S, Verkuijlen SAWM, Stathi P, Groenewegen NJ, Hijmering NJ, Berry DRAI, Meershoek EJ, Hoogmoed D, Kwakman A, Molenaar TJ, Pegtel DM, Ylstra B, de Jong D, Zijlstra JM, Roemer MGM. Drees EEE, et al. Among authors: borchmann s. Hemasphere. 2022 Jul 4;6(7):e749. doi: 10.1097/HS9.0000000000000749. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35813096 Free PMC article. No abstract available.
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sobesky S, Mammadova L, Cirillo M, Drees EEE, Mattlener J, Dörr H, Altmüller J, Shi Z, Bröckelmann PJ, Weiss J, Kreissl S, Sasse S, Ullrich RT, Reinke S, Klapper W, Gerhard-Hartmann E, Rosenwald A, Roemer MGM, Nürnberg P, Hagenbeek A, Zijlstra JM, Pegtel DM, Engert A, Borchmann P, von Tresckow B, Borchmann S. Sobesky S, et al. Among authors: borchmann s. Med. 2021 Oct 8;2(10):1171-1193.e11. doi: 10.1016/j.medj.2021.09.002. Med. 2021. PMID: 35590205 Free article.
44 results